Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Investing Activities: 2011-2025

Historic Cash from Investing Activities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to -$129.3 million.

  • Arrowhead Pharmaceuticals' Cash from Investing Activities rose 132.58% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.3 million, marking a year-over-year increase of 69.22%. This contributed to the annual value of -$129.3 million for FY2025, which is 69.22% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$129.3 million for FY2025, which was up 69.22% from -$420.1 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Cash from Investing Activities' 5-year high stood at -$5.4 million during FY2022, with a 5-year trough of -$420.1 million in FY2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$129.3 million (2025), whereas its average is -$215.2 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Cash from Investing Activities skyrocketed by 96.18% in 2022, and later crashed by 1,675.06% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$141.7 million in 2021, then surged by 96.18% to -$5.4 million in 2022, then plummeted by 1,675.06% to -$96.2 million in 2023, then plummeted by 336.87% to -$420.1 million in 2024, then spiked by 69.22% to -$129.3 million in 2025.